[Diagnosis and management of central nervous system infections in pediatric cancer patients].
Infections of the central nervous system (CNS) are a common cause of neurological abnormalities in pediatric oncology patients apart from cancer disease of the CNS. Often symptoms do not present unequivocally, impeding a clear distinction from other differential diagnosis. Repeated neurological examinations of the patient allow selecting the necessary laboratory tests and imaging techniques. As delayed antiinfectious treatment is associated with high mortality and severe sequelae of survivors, patients do need empirical therapy using adequate doses until diagnostic results allow a more specific treatment. This article provides the recommendations of the Infectious Diseases Working Party of the German Society for Pediatric Infectious Diseases (DGPI) and the German Society for Pediatric Hematology/Oncology (GPOH) for diagnosis and treatment of infections of the CNS in immunocompromised patients.
Hernárz Driever
P
P
Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie, Charité-Universitätsmedizin Berlin. pablo.hernaiz@charite.de
Reich
S
S
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002494:Central Nervous System Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D002648:Child; D003131:Combined Modality Therapy / Q000009:adverse effects; D003937:Diagnosis, Differential; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D009460:Neurologic Examination; D009503:Neutropenia / Q000139:chemically induced* / Q000150:complications; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011379:Prognosis
D000890:Anti-Infective Agents; D000970:Antineoplastic Agents